Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid CancerSamuel A. Wells, Martin Schlumberger, James R. Vasselli et al.|Journal of Clinical Oncology|2010Cited by 517
Vandetanib (100 mg) in Patients with Locally Advanced or Metastatic Hereditary Medullary Thyroid CancerBruce G. Robinson, Robert I. Haddad, Luis Paz‐Ares et al.|The Journal of Clinical Endocrinology & Metabolism|2010Cited by 255
Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3John D. Powderly, Bartosz Chmielowski, Gregory M. Coté et al.|Journal for ImmunoTherapy of Cancer|2015Cited by 101
A phase II open-label study of vandetanib in patients with locally advanced or metastatic hereditary medullary thyroid cancerRobert I. Haddad, Benjamin M. Robinson, James R. Vasselli et al.|Journal of Clinical Oncology|2008Cited by 37